Study of TYK-00540 Tablets in Patients With Advanced Solid Tumors
A phase 1/2 trial of TYK-00540 in HR-positive / HER2-negative breast cancer, run by TYK Medicines, Inc, now recruiting.
Overview
Study of TYK-00540 Tablets in Patients With Advanced Solid Tumors is a phase 1/2 interventional study registered as NCT06950086 by TYK Medicines, Inc, with 180 participants planned, started 2024-01-02 and due to reach its primary completion in 2026-09. Interventions recorded: TYK-00540.
Similar pages
not linked directly; found by shared links- TrialA Study to Learn More About How Well Elinzanetant Works and How Safe it is Compared to Placebo for the Treatment of Hot Flashes Caused by Anti-cancer Therapy in Women With, or at High Risk for Developing Hormone-receptor Positive Breast Cancer
Shares HR-positive / HER2-negative breast cancer and the tag pipeline.
- TrialA Study Comparing BL-M07D1 With DS-8201 in Patients With HR-Positive, HER2-Low Expressing Recurrent/Metastatic Breast Cancer
Shares HR-positive / HER2-negative breast cancer and the tag pipeline.
- TrialA Study of Dato-DXd in Inoperable or Metastatic Hormone Receptor-positive, HER2 IHC 0 Breast Cancer
Shares HR-positive / HER2-negative breast cancer and the tag pipeline.
- TrialComparison of Fulvestrant (FASLODEX™) 250 mg and 500 mg in Postmenopausal Women With Oestrogen Receptor Positive Advanced Breast Cancer Progressing or Relapsing After Previous Endocrine Therapy.
Shares HR-positive / HER2-negative breast cancer and the tag pipeline.
- TrialDNA-guided Second Line Adjuvant Therapy for High Residual Risk, Estrogen Receptor Positive, HER-2 Negative Breast Cancer (DARE)
Shares HR-positive / HER2-negative breast cancer and the tag pipeline.
- Trial(Z)-Endoxifen for the Treatment of Premenopausal Women With ER+/HER2- Breast Cancer
Shares HR-positive / HER2-negative breast cancer and the tag pipeline.
- TrialA Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer
Shares HR-positive / HER2-negative breast cancer and the tag pipeline.
- TrialEfficacy and Safety of Tinengotinib Tablets Combined With Fulvestrant Injection in Patients With HR Positive and HER-2 Negative Recurrent or Metastatic Breast Cancer Who Have Failed Prior Treatment
Shares HR-positive / HER2-negative breast cancer and the tag pipeline.